“Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1”, J of Skin, vol. 4, no. 5, p. s40, Sep. 2020, doi: 10.25251/skin.4.supp.40.